MA28064A1 - Dérivés de pyrrolo [3,4-c] pyrazole actifs comme inhibiteurs de kinases - Google Patents

Dérivés de pyrrolo [3,4-c] pyrazole actifs comme inhibiteurs de kinases

Info

Publication number
MA28064A1
MA28064A1 MA28721A MA28721A MA28064A1 MA 28064 A1 MA28064 A1 MA 28064A1 MA 28721 A MA28721 A MA 28721A MA 28721 A MA28721 A MA 28721A MA 28064 A1 MA28064 A1 MA 28064A1
Authority
MA
Morocco
Prior art keywords
pyrrolo
pyrazole derivatives
kinase inhibitors
derivatives active
active
Prior art date
Application number
MA28721A
Other languages
English (en)
Inventor
Daniele Fancelli
Barbara Forte
Jurgen Moll
Mario Varasi
Paola Vianello
Original Assignee
Pharmacia Italia Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Italia Spa filed Critical Pharmacia Italia Spa
Publication of MA28064A1 publication Critical patent/MA28064A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Dérivés de pyrrolo[3,4-c]pyrazole actifs comme inhibiteurs de kinases Des dérivés de pyrrolo[3,4-c]pyrazole de formule (1) et leurs sels pharmaceutiquement acceptables, tels que définis dans le présent mémoire, un procédé pour leur préparation et des compositions pharmaceutiques les contenant sont décrits; les composés de la présente invention peuvent être utiles, en thérapeutique, dans le traitement de maladies associées à une dérégulation d'activité de protéine-kinases, telles que le cancer.
MA28721A 2003-07-09 2006-01-09 Dérivés de pyrrolo [3,4-c] pyrazole actifs comme inhibiteurs de kinases MA28064A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US48581403P 2003-07-09 2003-07-09

Publications (1)

Publication Number Publication Date
MA28064A1 true MA28064A1 (fr) 2006-08-01

Family

ID=34062099

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28721A MA28064A1 (fr) 2003-07-09 2006-01-09 Dérivés de pyrrolo [3,4-c] pyrazole actifs comme inhibiteurs de kinases

Country Status (41)

Country Link
US (2) US7141568B2 (fr)
EP (1) EP1644376B1 (fr)
JP (1) JP4728232B2 (fr)
KR (1) KR101075711B1 (fr)
CN (1) CN100564380C (fr)
AP (1) AP2214A (fr)
AR (1) AR050045A1 (fr)
AT (1) ATE480540T1 (fr)
AU (1) AU2004255347B2 (fr)
BR (1) BRPI0411868B8 (fr)
CA (1) CA2531759C (fr)
CR (1) CR8171A (fr)
CY (1) CY1110832T1 (fr)
DE (1) DE602004029045D1 (fr)
DK (1) DK1644376T3 (fr)
DO (1) DOP2004000949A (fr)
EA (1) EA009462B1 (fr)
EC (1) ECSP056246A (fr)
ES (1) ES2349780T3 (fr)
GE (1) GEP20084395B (fr)
GT (2) GT200400133AA (fr)
HN (1) HN2004000232A (fr)
IL (1) IL172923A (fr)
IS (1) IS2843B (fr)
MA (1) MA28064A1 (fr)
ME (1) MEP51908A (fr)
MX (1) MXPA06000362A (fr)
MY (1) MY139072A (fr)
NO (1) NO332361B1 (fr)
NZ (1) NZ544514A (fr)
PA (1) PA8606201A1 (fr)
PE (1) PE20050325A1 (fr)
PL (1) PL1644376T3 (fr)
PT (1) PT1644376E (fr)
RS (2) RS20060004A (fr)
SI (1) SI1644376T1 (fr)
TN (1) TNSN06009A1 (fr)
TW (1) TWI343382B (fr)
UA (1) UA81682C2 (fr)
WO (1) WO2005005427A1 (fr)
ZA (1) ZA200600095B (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100904157B1 (ko) * 2000-08-10 2009-06-23 파마시아 이탈리아 에스.피.에이. 키나제 억제제로서 활성인 비사이클로-피라졸, 이의제조방법 및 이를 포함하는 약제학적 조성물
WO2005030776A1 (fr) * 2003-09-23 2005-04-07 Vertex Pharmaceuticals Incorporated Derives de pyrazolopyrrole utilises en tant qu'inhibiteurs de proteines kinases
US7572914B2 (en) * 2003-12-19 2009-08-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
EP1763524A1 (fr) * 2004-04-23 2007-03-21 Takeda San Diego, Inc. Derives d'indole et leur utilisation en tant qu'inhibiteurs de kinases
WO2006023931A2 (fr) * 2004-08-18 2006-03-02 Takeda San Diego, Inc. Inhibiteurs de kinase
US7713973B2 (en) * 2004-10-15 2010-05-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
SI1838718T1 (sl) 2005-01-10 2011-08-31 Pfizer Pirolopirazoli, zmogljivi inhibitorji kinaze
US8119655B2 (en) * 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
TW200808311A (en) * 2006-03-30 2008-02-16 Nerviano Medical Sciences Srl Use of a kinase inhibitor for the treatment of particular resistant tumors
WO2008017465A1 (fr) * 2006-08-10 2008-02-14 F. Hoffmann-La Roche Ag Dérivés de lactame bicycliques, leur fabrication et utilisation en tant qu'agents pharmaceutiques
GEP20135728B (en) 2006-10-09 2013-01-25 Takeda Pharmaceuticals Co Kinase inhibitors
EP2223925A1 (fr) * 2006-10-09 2010-09-01 Takeda Pharmaceutical Company Limited Inhibiteurs de kinase
US20100256160A1 (en) * 2006-11-03 2010-10-07 Nerviano Medical Sciences S.R.L. Method of administering an antitumor compound
AR071780A1 (es) * 2008-05-15 2010-07-14 Nerviano Medical Sciences Srl Derivados de carbamoilo de carbonilamino-pirazoles biciclicos como profarmacos
WO2010009985A2 (fr) 2008-07-24 2010-01-28 Nerviano Medical Sciences S.R.L. Combinaison thérapeutique renfermant un inhibiteur de la kinase aurora et des agents antiprolifératifs
CN102105147B (zh) * 2008-07-24 2013-07-03 内尔维阿诺医学科学有限公司 包含aurora激酶抑制剂和抗肿瘤药的治疗组合
US20100022553A1 (en) * 2008-07-24 2010-01-28 Nerviano Medical Sciences S.R.L. Therapeutic Combination Comprising an Aurora Kinase Inhibitor and Imatinib
MX2011006725A (es) 2008-12-22 2011-09-15 Millennium Pharm Inc Combinacion de inhibidores de aurora cinasa y anticuerpos anti-cd20.
WO2013088257A1 (fr) 2011-12-12 2013-06-20 Dr. Reddy's Laboratories Ltd. Composés hétérocycliques substitués en tant qu'inhibiteurs du récepteur kinase a lié à la tropomyosine (trka)
CN104072498B (zh) * 2013-03-26 2016-12-28 沈阳药科大学 （R）‑N‑[5‑(2‑甲氧基‑2‑苯基乙酰基)‑1,4,5,6‑四氢吡咯并[3,4‑c]吡唑‑3‑基]‑4‑(4‑甲基哌嗪‑1‑基)苯甲酰胺的合成方法
US10335494B2 (en) 2013-12-06 2019-07-02 Millennium Pharmaceuticals, Inc. Combination of aurora kinase inhibitors and anti-CD30 antibodies
EP3157921A1 (fr) 2014-06-23 2017-04-26 Dr. Reddy's Laboratories Ltd. Composés d'imidazo [1,2-a]pyridine substitués utiles pour le traitement de la douleur
EP3309163A4 (fr) 2015-06-15 2019-01-09 UBE Industries, Ltd. Dérivé de dihydropyrrolopyrazole substitué
JP2018524292A (ja) 2015-07-21 2018-08-30 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． オーロラキナーゼインヒビターと化学療法剤の投与
CN107337674B (zh) * 2016-04-29 2019-09-20 江苏吉贝尔药业股份有限公司 用于dpp-iv抑制剂的四氢吡喃胺衍生物、其药物组合物和制剂以及用途
US11874276B2 (en) 2018-04-05 2024-01-16 Dana-Farber Cancer Institute, Inc. STING levels as a biomarker for cancer immunotherapy
US20220305048A1 (en) 2019-08-26 2022-09-29 Dana-Farber Cancer Institute, Inc. Use of heparin to promote type 1 interferon signaling
CN113563346A (zh) * 2021-08-19 2021-10-29 守恒(厦门)医疗科技有限公司 吡咯[3,4-c]并吡唑二酰胺类衍生物及其在抗肿瘤药物中的应用
CA3247864A1 (fr) 2022-04-07 2023-10-12 Eli Lilly And Company Procédé de fabrication d'un inhibiteur de sarcome de rat de kirsten g12c
EP4504209A1 (fr) 2022-04-08 2025-02-12 Eli Lilly and Company Méthode de traitement comprenant des inhibiteurs de kras g12c et des inhibiteurs d'aurora a
IL317823A (en) 2022-06-30 2025-02-01 Lilly Co Eli KRAS G12C inhibitor for cancer treatment

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2717380B1 (fr) * 1994-03-15 1996-04-26 Oreal Compositions cosmétiques contenant un mélange synergétique de polymères conditionneurs.
GB9911053D0 (en) 1999-05-12 1999-07-14 Pharmacia & Upjohn Spa 4,5,6,7-tetrahydroindazole derivatives process for their preparation and their use as antitumour agents
DE19932144A1 (de) * 1999-07-09 2001-01-11 Basf Ag Mikrokapselzubereitungen und Mikrokapseln enthaltende Wasch- und Reinigungsmittel
GEP20053476B (en) 1999-08-12 2005-03-25 Upjohn Co 3(5)-Amino-Pyrazole Derivatives, Process for Their Preparation and Their Use as Antitumor Agents
US6387900B1 (en) 1999-08-12 2002-05-14 Pharmacia & Upjohn S.P.A. 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents
KR100904157B1 (ko) 2000-08-10 2009-06-23 파마시아 이탈리아 에스.피.에이. 키나제 억제제로서 활성인 비사이클로-피라졸, 이의제조방법 및 이를 포함하는 약제학적 조성물
FR2815032B1 (fr) 2000-10-10 2003-08-08 Pf Medicament Nouveaux derives d'aminophenyle piperazine ou d'amino phenyle piperide inhibiteurs de proteines prenyl transferase ainsi que leurs preparations
US20040019046A1 (en) 2000-11-27 2004-01-29 Paolo Pevarello Phenylacetamido-pyrazole derivatives and their use as antitumor agents
EP1379524A2 (fr) 2001-01-26 2004-01-14 Pharmacia Italia S.p.A. Derives de chromane, procede de preparation et d'utilisation de ces derives en tant qu'agents antitumoraux
ES2357502T3 (es) 2001-09-26 2011-04-27 Pfizer Italia S.R.L. Derivados de aminoindazol activos como inhibidores de quinasa, procedimiento para su preparación y composiciones farmaceuticas que los contienen.
AU2003244632A1 (en) 2002-07-25 2004-02-25 Pharmacia Italia S.P.A. Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them

Also Published As

Publication number Publication date
AP2214A (en) 2011-03-04
CA2531759C (fr) 2013-04-02
AU2004255347A1 (en) 2005-01-20
CY1110832T1 (el) 2015-06-10
DE602004029045D1 (de) 2010-10-21
PE20050325A1 (es) 2005-05-17
MY139072A (en) 2009-08-28
CN100564380C (zh) 2009-12-02
GT200400133AA (es) 2007-07-10
NO332361B1 (no) 2012-09-03
BRPI0411868B8 (pt) 2021-05-25
RS20060004A (sr) 2008-06-05
TNSN06009A1 (fr) 2007-10-03
PL1644376T3 (pl) 2011-03-31
CR8171A (es) 2006-08-09
EA009462B1 (ru) 2007-12-28
US7141568B2 (en) 2006-11-28
ECSP056246A (es) 2006-04-19
CN1820009A (zh) 2006-08-16
AP2006003480A0 (en) 2006-02-28
GEP20084395B (en) 2008-06-10
TW200510385A (en) 2005-03-16
MEP51908A (en) 2011-05-10
US7582628B2 (en) 2009-09-01
JP2009513525A (ja) 2009-04-02
UA81682C2 (en) 2008-01-25
IL172923A (en) 2011-09-27
NZ544514A (en) 2009-07-31
NO20060113L (no) 2006-04-05
DOP2004000949A (es) 2005-01-15
CA2531759A1 (fr) 2005-01-20
EA200600209A1 (ru) 2006-06-30
KR20060033001A (ko) 2006-04-18
AR050045A1 (es) 2006-09-27
BRPI0411868A (pt) 2006-08-08
TWI343382B (en) 2011-06-11
IL172923A0 (en) 2006-06-11
US20050032839A1 (en) 2005-02-10
RS52155B (sr) 2012-08-31
BRPI0411868B1 (pt) 2019-11-12
IS8192A (is) 2005-12-22
MXPA06000362A (es) 2006-03-28
HK1089769A1 (en) 2006-12-08
PT1644376E (pt) 2010-09-24
PA8606201A1 (es) 2005-08-04
ES2349780T3 (es) 2011-01-11
SI1644376T1 (sl) 2010-11-30
IS2843B (is) 2013-08-15
KR101075711B1 (ko) 2011-10-21
HN2004000232A (es) 2011-01-17
US20060276471A1 (en) 2006-12-07
EP1644376A1 (fr) 2006-04-12
WO2005005427A1 (fr) 2005-01-20
EP1644376B1 (fr) 2010-09-08
JP4728232B2 (ja) 2011-07-20
AU2004255347B2 (en) 2010-04-08
ZA200600095B (en) 2007-01-31
ATE480540T1 (de) 2010-09-15
DK1644376T3 (da) 2011-01-03
GT200400133A (es) 2005-04-18

Similar Documents

Publication Publication Date Title
MA28064A1 (fr) Dérivés de pyrrolo [3,4-c] pyrazole actifs comme inhibiteurs de kinases
TNSN05298A1 (fr) Derives de pyrazolo-quinazoline, procede pour leur preparation et leur utilisation comme inhibiteurs de kinases
MA27711A1 (fr) Derives de pyrazolo [1,5-a] pyrimidine
MA27703A1 (fr) Derives de diazepino-indole servant d'inhibiteurs de kinases
MA27389A1 (fr) Derives de benzimidazole nouveaux utiles comme agents antiproliferatifs.
TNSN05250A1 (fr) Pyrimidinones substituees
MA28429B1 (fr) Dérivés de 1H-thiéno [2,3-c] pyrazole utiles comme inhibiteurs de kinases
MA29713B1 (fr) Derives de tetrahydroindolone et de tetrahydroindazolone
MA65277B1 (fr) Inhibiteurs de l'inflammasome nlrp3
US20090275586A1 (en) Heterocyclic inhibitors of pde4
IL182893A0 (en) PYRAZOLO-[1,5-a] PYRIMIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
MA27568A1 (fr) Derives de pyrrolopyrimidine
TNSN04156A1 (fr) Pyridinones substituees servant de modulateurs de la map-kinase p38
PL1678166T3 (pl) Inhibitory kinaz białkowych
BRPI0017548A2 (pt) Composto, e, processo para a preparação de um composto
MA26727A1 (fr) Derives nouveaux de pyrimidine inhibiteurs de sorbitol deshydrogenase, leur procede de preparation et compositions pharmaceutiques les contenant
MA28270A1 (fr) Pyrido [2, 3-D] pyrimidine-2, 4-diamines servant d'inhibiteurs de PDE 2
TNSN00239A1 (fr) DERIVES DE PYRROLO [2,3-d] PYRIMIDINE NOUVEAUX, ET COMPOSITIONS LES CONTENANT
TNSN01095A1 (fr) DERIVES DE PYRROLO [2,3-d] PYRIMIDINE NOUVEAUX ET COMPOSITIONS LES CONTENANT
MA32009B1 (fr) Nouveaux derives de pyrazolo [3,4-d]pyrimidine en tant qu'agents anticancereux
MA27093A1 (fr) Derives de sulfonamides, leur preparation et leur application comme medicaments.
MA26868A1 (fr) Pyrido[2,3-d]pyrimidine-2,7-diamines inhibitrices de kinases
MA56883B1 (fr) Dérivés de 2-hydroxycycloalcane-1-carbamoyle
MA28742B1 (fr) Derives de pyrido-pyrimidine, leur preparation, leur application en therapeutique
TNSN00235A1 (fr) Derives d'heterocyclo-alkylsulfonylpyrazole nouveaux, procede pour leur preparation et compositions les contenant